SynthesisQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2026
Cough, dyspnea, or chest pain? an examination of the composite endpoint in metastatic non-small cell lung cancer clinical trials.
Synthesis in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMany clinical trials of metastatic non-small cell lung cancer (mNSCLC) include a composite endpoint of cough, chest pain and dyspnea to assess patient-reported symptomatic deterioration using time-to-confirmed deterioration (TTCD) analyses. We sought to determine the robustness of this composite, and whether composites involving other patient-relevant symptoms of mNSCLC are more sensitive to progression.
methodsData from nine mNSCLC trials with the EORTC QLQ-C30 and QLQ-LC13 were pooled. Spearman's correlation coefficients were used to assess associations between symptoms. Composites were evaluated based on the number of confirmed deterioration (CD) events, median TTCD, and positive predictive value (PPV) against progression-free survival (PFS).
results5,157 patients with mNSCLC with at least one PRO assessment were included. Cough and dyspnea were frequently reported at baseline (79.8% and 67.8%, respectively) and moderately correlated (0.37), while chest pain was less common (41.5%) and showed weaker associations. The composite of cough, chest pain, and dyspnea had a median TTCD of 8 three-week treatment cycles and PPV of 78.3%. Composites including symptoms such as fatigue and general pain reached median TTCD earlier while maintaining high PPVs (78.3-81.3%). The median TTCD for single-item dyspnea was 50 cycles but was not reached for cough and chest pain.
conclusionsThe composite of cough, chest pain, and dyspnea displayed strong properties; however, composites obscure the time course of included symptoms. Although median TTCD is reached earlier with a composite endpoint, greater clarity is obtained when symptoms are studied individually.
Indexed as
Identifiers
42319550What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.